Troxipide is an antiulcerative agent. It inhibits production of superoxide induced by N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP; Item No. 21495) in, and IL-8-induced migration of, isolated human polymorphonuclear (PMN) neutrophils when used at a concentration of 1 mM. Troxipide (100 and 200 mg/kg, i.p.) reduces the lesion size of gastric ulcers induced by diclofenac (Item Nos. 70680 | 22983) in rats.
Troxipide is an antiulcerative agent. It inhibits production of superoxide induced by N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP; Item No. 21495) in, and IL-8-induced migration of, isolated human polymorphonuclear (PMN) neutrophils when used at a concentration of 1 mM. Troxipide (100 and 200 mg/kg, i.p.) reduces the lesion size of gastric ulcers induced by diclofenac (Item Nos. 70680 | 22983) in rats.
Shipping & Handling
Shipped In
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.